Given the potential of TLR8 and TNFSF9 as new targets for cancer immunotherapy36,41, how specific HLA-I genotypes influence their expression in tumor microenvironment and the role of HLA-A02+B62+B44− in treatment outcomes of related drugs targeting TLR8 or TNFSF9 deserve to be further studied. This evidence concerns the gene TNFSF9 and neoplasm.